Palatin Technologies, Inc. has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $10,000,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Palatin Technologies, Inc. is raising $10,000,000.00 in new funding. About Palatin Technologies, Inc.: Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
To learn more about Palatin Technologies, Inc., visit http://palatin.com/
Contact:
Carl Spana, President and Chief Executive Officer
609-495-2200
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.